While TNF-α inhibitors have not shown definitive efficacy in reducing mortality when considering both RCTs and non-randomised studies, the RCTs alone demonstrated a statistically significant reduction in mortality among patients with moderate-to-critical COVID-19 treated with TNF-α inhibitor therapy. The gene discussed is TNF; the disease is COVID-19.